Mifepristone provision following policy shifts in 2022 and 2023.

Strasser J, Gorak T, Griffin R, Luckenbill S, Schenk E, Luo QE

DOI: 10.1016/j.contraception.2026.111545
Published: 2026 Jun 28
Container: Contraception
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.contraception.2026.111545,
  title = {Mifepristone provision following policy shifts in 2022 and 2023.},
  author = {Strasser J and Gorak T and Griffin R and Luckenbill S and Schenk E and Luo QE},
  year = {2026},
  journal = {Contraception},
  doi = {10.1016/j.contraception.2026.111545},
  url = {https://doi.org/10.1016/j.contraception.2026.111545}
}

RIS

TY  - JOUR
TI  - Mifepristone provision following policy shifts in 2022 and 2023.
AU  - Strasser J
AU  - Gorak T
AU  - Griffin R
AU  - Luckenbill S
AU  - Schenk E
AU  - Luo QE
PY  - 2026
JO  - Contraception
DO  - 10.1016/j.contraception.2026.111545
UR  - https://doi.org/10.1016/j.contraception.2026.111545
ER  -

APA

J, S., T, G., R, G., S, L., E, S., & QE, L. (2026). Mifepristone provision following policy shifts in 2022 and 2023.. Contraception. https://doi.org/10.1016/j.contraception.2026.111545

Source records

pubmed · retrieved 2026-09-26T09:40:22.455Z